Volume 28, Number 3—March 2022
Research
Retrospective Cohort Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020
Tasnim Hasan
, Viet Nhung Nguyen, Hoa Binh Nguyen, Thu Anh Nguyen, Hien T.T. Le, Cuong D. Pham, Nam Hoang, Phuong T.M. Nguyen, Justin Beardsley, Guy B. Marks, and Greg J. Fox
, Viet Nhung Nguyen, Hoa Binh Nguyen, Thu Anh Nguyen, Hien T.T. Le, Cuong D. Pham, Nam Hoang, Phuong T.M. Nguyen, Justin Beardsley, Guy B. Marks, and Greg J. Fox
Table 2
Tuberculosis treatment outcomes for patients receiving first-line therapy, stratified by date treatment began, Vietnam*
| Treatment start date | Favorable outcome† | Failure | Lost to follow-up | Death | Transfer to MDR‡ | Not evaluated | Total unfavorable outcome§ |
|---|---|---|---|---|---|---|---|
| 2016 | |||||||
| Q1 | 18,405 (92.9) | 146 (0.7) | 434 (2.2) | 545 (2.8) | 31 (0.2) | 252 (1.3) | 1,156 (5.8) |
| Q2 | 20,943 (93.3) | 129 (0.6) | 567 (2.5) | 531 (2.4) | 47 (0.2) | 235 (1.0) | 1,274 (5.7) |
| Q3 | 22,656 (93.5) | 139 (0.6) | 580 (2.4) | 535 (2.2) | 56 (0.2) | 258 (1.1) | 1,310 (5.4) |
| Q4 | 24,106 (91.6) | 192 (0.7) | 700 (2.7) | 667 (2.5) | 103 (0.4) | 562 (2.1) | 1,662 (6.3) |
| Total 2016 |
86,110 (92.8) |
606 (0.7) |
2,281 (2.5) |
2,278 (2.5) |
237 (0.3) |
1,307 (1.4) |
5,402 (5.8) |
| 2017 | |||||||
| Q1 | 22,453 (91.0) | 193 (0.8) | 676 (2.7) | 557 (2.3) | 103 (0.4) | 694 (2.8) | 1,529 (6.2) |
| Q2 | 24,863 (91.5) | 188 (0.7) | 686 (2.5) | 632 (2.3) | 102 (0.4) | 715 (2.6) | 1,608 (5.9) |
| Q3 | 25,813 (92.3) | 170 (0.6) | 712 (2.5) | 615 (2.2) | 107 (0.4) | 549 (2.0) | 1,604 (5.7) |
| Q4 | 23,171 (91.6) | 119 (0.5) | 652 (2.6) | 613 (2.4) | 120 (0.5) | 615 (2.4) | 1,504 (5.9) |
| Total 2017 |
96,300 (91.6) |
670 (0.6) |
2,726 (2.6) |
2,417 (2.3) |
432 (0.4) |
2,573 (2.4) |
6,245 (5.9) |
| 2018 | |||||||
| Q1 | 21,514 (90.9) | 164 (0.7) | 624 (2.6) | 669 (2.8) | 114 (0.5) | 573 (2.4) | 1,571 (6.6) |
| Q2 | 23,942 (91.4) | 129 (0.5) | 691 (2.6) | 648 (2.5) | 159 (0.6) | 623 (2.4) | 1,627 (6.2) |
| Q3 | 24,221 (91.6) | 135 (0.5) | 668 (2.5) | 640 (2.4) | 127 (0.5) | 657 (2.5) | 1,570 (5.9) |
| Q4 | 23,575 (91.1) | 122 (0.5) | 691 (2.7) | 615 (2.4) | 108 (0.4) | 758 (2.9) | 1,536 (5.9) |
| Total 2018 |
93,252 (91.3) |
550 (0.5) |
2,674 (2.6) |
2,572 (2.5) |
508 (0.5) |
2,611 (2.6) |
6,304 (6.2) |
| 2019 | |||||||
| Q1 | 21,842 (90.4) | 144 (0.6) | 748 (3.1) | 624 (2.6) | 110 (0.5) | 701 (2.9) | 1,626 (6.7) |
| Q2 | 24,122 (90.7) | 155 (0.6) | 777 (2.9) | 701 (2.6) | 150 (0.6) | 680 (2.6) | 1,783 (6.7) |
| Q3 | 25,525 (91.3) | 123 (0.4) | 784 (2.8) | 632 (2.3) | 183 (0.7) | 724 (2.6) | 1,722 (6.2) |
| Q4 | 23,501 (91.0) | 124 (0.5) | 681 (2.6) | 614 (2.4) | 166 (0.6) | 729 (2.8) | 1,585 (6.1) |
| Total 2019 |
73,148 (91.0) |
402 (0.5) |
2,242 (2.8) |
1,947 (2.4) |
499 (0.6) |
2,133 (2.7) |
5,090 (6.3) |
| 2020¶ | |||||||
| Q1 | 21,613 (91.2) | 144 (0.6) | 516 (2.2) | 643 (2.7) | 156 (0.7) | 623 (2.6) | 1,459 (6.2) |
*Values are no. (%). MDR, multidrug-resistant; Q, quarter. †Favorable outcomes include cure and treatment complete. ‡Cases were transferred to MDR status when resistance testing revealed MDR TB or treatment with first-line antimicrobial drugs failed. §Unfavorable outcomes include failure, loss to follow-up, death, and transfer to MDR. ¶For 2020, only outcomes for Q1 were available.
Page created: February 04, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.